Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Icario is a private, private-equity-backed digital health company that provides a cloud-based health action and member engagement platform for health plans and providers. The company focuses on motivating people to complete health risk assessments, close preventive and chronic care gaps, respond to CAHPS and HOS surveys, and engage with rewards and incentive programs. Icario was created through the 2020 combination of Revel and NovuHealth and later took on majority investment from CVC Capital Partners in 2021. In 2025, the company launched Aivella, a platform-as-a-service offering that unifies member engagement workflows, data infrastructure, analytics, and API-based integration. Icario operates nationally in the United States and primarily serves payer and provider customers rather than developing therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Icario.